Meeting Agenda

Day One (Rotavirus session)

08:30-09:00Registration

Opening Session

Moderators: Yu-Mei Wen / Roger Glass

  • 09:00-09:10
    Welcome Note and Introduction

    Yu-Mei Wen

    Key Laboratory of Medical Molecular Virology of MoE & MoH, School of

    Basic Medical Sciences, Fudan University

  • 09:10-09:20
    Opening Remarks

    Zi-Jian Feng

    China Center for Diseases Control and Prevention

  • 09:20-09:40
    Introduction of Global RV immunization

    Roger Glass

    US National Institute of Health

  • 09:40-10:00
    Overview of RV surveillance and burden worldwide

    Adam Cohen

    World Health Organization

  • 10:00-10:20
    The unmet demands for vaccines against AGE, Global Perspective

    Duncan Steele

    Bill & Melinda Gates Foundation

10:20-10:50 Coffee Break and Group Photo

Session One: Implementation of RV vaccine: experience, current status and prospect

Moderators: Zi-Jian Feng / Duncan Steele

  • 10:50-11:10
    The implementation of RV vaccine in China: current status

    Hua-Qing Wang

    China Center for Diseases Control and Prevention

  • 11:10-11:30
    The implementation of RV vaccine in Hong Kong

    Tony Nelson

    The Chinese University of HongKong

  • 11:30-11:50
    The implementation of RV vaccine in Taiwan

    Fang-Tzy Wu

    Center for Diseases Control and Prevention, Taiwan, China

  • 11:50-12:10

    Hospital-based surveillance and genetic characterization of RV

    among Children in China: 2009-2016

    Na Liu

    China Center for Diseases Control and Prevention

12:30-13:30 Lunch

Session Two: Safety, Efficacy and Impact of RV Vaccines

Moderators:Huan Yang / You-Chun Wang

  • 13:00-13:20
    Evaluation of vaccine in China: an overview

    Huan Yang

    Center for Drug Evaluation, CFDA

  • 13:20-13:40

    Impact of universal immunization with replicable vaccines worldwide

    reduction of disease burden, spread and variation of vaccine strains, and its

    implication for public health

    Umesh Parashar

    US Center for Diseases Control and Prevention

  • 13:40-14:00
    Development of RV vaccine in Vietnam

    Duc Anh Dang

    National Institute for Hygiene and Epidemiology, Vietnam

  • 14:00-14:20
    Replicable vaccines and intussusception

    Jackie Tate

    US Center for Diseases Control and Prevention

  • 14:20-14:40

    Trivalent reassortant vaccine developed by Lanzhou Vaccine Institute: Results

    from phase III trial

    Li Yu

    China National Biotec Group Company Limited, Lanzhou

  • 14:40-15:00

    Hexavalent reassortant vaccine development by Wuhan Vaccine Institute:

    pre-clinical and preliminary clinical results

    Gelin Xu

    China National Biotec Group Company Limited, Wuhan

  • 15:20-15:40

    Efficacy and effectiveness of RotaTeq: results from pre-licensure and

    post-marketing studies

    TBD
  • 15:40-16:00
    RotaRix
    TBD
  • 16:00-16:20
    New strategy for immunization with a tetravalent rotavirus vaccine in early life

    Michel Klein

    BravoVax Co, Ltd

16:20-16:40 Coffee Break

Session Three: development of next generation vaccines

Moderators: Xiao-Ming Yang / Bao-Ming Jiang

  • 16:40-17:00

    Non-replicating rotavirus vaccines and

    new technology: rationale and current landscape

    Baoming Jiang

    US Center for Diseases Control and Prevention

  • 17:00-17:20
    RV evolution and recombinant subunit vaccine

    Xi Jason Jiang

    Cincinnati Children’s Hospital Medical Center, University of

    Cincinnati, College of Medicine

  • 17:20-17:40
    Development of inactivated RV vaccine

    Mao-Sheng Sun

    Institute of Medical Biology, Chinese Academy of Medicine Science &

    Peking Union Medical College

  • 17:40-18:40

    Panel Discussion and Wrap-up:

    - Advocacy for universal immunization of RV vaccines in China: challenges and future directions

    - Issues for future clinical development of RV vaccine in China

    Concerns about intussusception?

    China specific Severity Score System?

18:30Welcome Reception Xi Yuan Restaurant, Fenglin Campus

Day Two (Norovirus session)

Session One: Epidemiology and Diseases Burden

Moderators: Xuan-Yi Wang / Umesh Parashar

  • 08:30-08:50
    Global burden and perspectives

    Adam Cohen

    World Health Organization

  • 08:50-09:10
    Disease burden caused by norovirus infections in China

    Xuan-Yi Wang

    Fudan University

  • 09:10-09:30
    Molecular epidemiology of norovirus in China

    Miao Jin

    China Center for Diseases Control and Prevention

  • 09:30-09:50
    Surveillance and disease Burden of AGE caused by norovirus in USA and worldwide

    Aron Hall

    US Center for Diseases Control and Prevention

  • 09:50-10:10
    Prevalence of norovirus in Taiwan

    Fang-Tzy Wu

    Center for Diseases Control and Prevention, Taiwan,China

  • 10:10-10:30

    Changing epidemiology of norovirus gastroenteritis in Hong Kong:

    a tug-of-war between GII.4 and non-GII.4 genotypes

    Martin Chan

    The Chinese University of HongKong

  • 10:30-10:50
    Characteristics and prevalence of norovirus infections in Shanghai

    Yun-Wen Hu

    Shanghai Public Clinical Center, Fudan University

10:50-11:10 Coffee Break

Session Two: Evolution and Immunity of Norovirus

Moderators: Zhao-Jun Duan / Robert Legare Atmar

  • 11:10-11:30
    Pathogenesis and immunity of norovirus infection

    Robert Legare Atmar

    Baylor College of Medicine

  • 11:30-11:50
    Association between HBGAs and rotavirus/norovirus

    Umesh Parashar

    US Center for Diseases Control and Prevention

  • 11:50-12:10
    Evolution of noroviruses

    Ming Tan

    Cincinnati Children’s Hospital Medical Center,

    University of Cincinnati

12:10-13:00 Lunch

Session Three: Development of NoV vaccines

Moderators: Xi Jason Jiang/ Adam Cohen

  • 13:00-13:20
    Clinical experiences from Taketa VLP vaccine

    Ted Tsai

    Takeda

  • 13:20-13:40
    TBD

    Shuo Shen

    China National Biotec Group Company Limited, Wuhan

  • 13:40-15:00

    Panel Discussion and Wrap-up:

    - Demand of NoV vaccines in China;

    - Challenges for R&D of NoV vaccines

    Evolution of virus

    Persistence of immunity

    Clinical Evaluation

Closing Session:

Moderators: Zhao-Jun Duan / Xuan-Yi Wang

  • Closing Remark

    TBD

    China Center for Diseases Control and Prevention

  • Closing Remark

    Zheng-Hong Yuan

    Fudan University